If you are currently on the lookout for stocks that have made considerable gains over the past month then one of the stocks to track at this point is that of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP).
Over the course of the past month, the Adamis stock has been in the middle of a strong rally and has managed to record gains of as much as 80% so far. This morning the company is in the news once again after Adamis sent out a letter addressed to its shareholders in relation to its product Tempol and its potency as a medicine that could treat COVID 19.
The company started the letter off by urging the shareholders to vote for all the five members of the Adamis board to be reinstated at the company’s Annual Meeting of Shareholders that is going to be held on July 16. The company revealed that continuity in the board is highly important as it pursues the development of its product Tempol.
In the letter, the company also pointed out that a recent study conducted by the National Institutes of Health has concluded that Tempol could be potentially used as an antiviral medicine against COVID 19. It will be interesting to see if the latest development leads to a strong movement in the Adamis stock or not.
Market Reaction:
As of 12:10, ADMP stock fell 2.60% to $1.20 with more than 5.46 million shares, compared to its average volume of 8.42 million shares. The stock has moved within a range of $ 1.1700 – 1.2800 after opening the trade at $1.24. Over the past 52-week, the stock has been trading within a range of $0.3800 – 2.3400.
 Stock Soars 80% in a Month: More to Come?){kind=link}